Nonalcoholic Fatty Liver Disease Clinical Trial
Official title:
Role of Pioglitazone and Berberine in Treatment of Non-alcoholic Fatty Liver Disease(NAFLD) Patients With Impaired Glucose Regulation or Type 2 Diabetes Mellitus
Verified date | June 2012 |
Source | Fudan University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the effects and safety of pioglitazone and berberine on the basis of lifestyle intervention to non-alcoholic fatty liver disease patients with impaired glucose regulation or type 2 diabetes mellitus.
Status | Completed |
Enrollment | 184 |
Est. completion date | August 2011 |
Est. primary completion date | August 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Patients must have an age range between 18 to 65 years (inclusive). 2. Patients with fatty liver confirmed by ultrasound. 3. Patients must meet the criteria for impaired glucose regulation or type 2 diabetes mellitus (FPG = 5.6 mmol/L and/or a two hour glucose value = 7.8 mmol/L). 4. Course of diabetic mellitus no more than 1 years 5. Diabetic patients have not received anti-diabetic drugs, including insulin, biguanides, sulfonylureas, thiazolidinediones, Alpha-glucosidase inhibitors, or glinides for 4 weeks before the time of enrollment 6. Patients have not received lipid-regulating drugs (statins, fibrates)for 4 weeks before the time of enrollment 7. Blood pressure < 160/100 mmHg,after receiving lifestyle therapy and effective anti-hypertensive drugs. 8. Patients must stopped other drugs medications for four weeks prior to entering the treatment period, such as: silybin, ursodeoxycholic acid, Polyene Phosphatidylcholine, vitamin E, some herbs with effect of regulating lipid and protecting liver function, etc. 9. Liver fat content(LFC) assessed by 1H MRS = 13%(LFC was calculated by dividing the integral of the methylene groups in fatty acid chains of the hepatic triglycerides by the sum of methylene groups and water). Exclusion Criteria: 1. Any causes of chronic liver disease other than NAFLD (such as - but not restricted to - alcohol or drug abuse, medication, chronic hepatitis B or C, autoimmune, etc.); 2. Patients with significantly impaired liver function: ALT or AST = 2 times upper limit of normal; 3. HBsAg (+) and/or HCV-Ab (+); 4. Patients with type 1 diabetes mellitus or gestational diabetes or special type diabetes, and patients with BMI < 22 Kg/m2; 5. Course of diabetes more than 1 years; 6. Diabetics patients who have taken or are taking oral glucose-lowering drugs or insulin; 7. Diabetics patients with a HbA1c > 7.5% on initial visit; 8. Patients with severe diabetes complications (diabetes ketoacidosis, diabetes coma or with symptomatic of diabetes coma; dysfunction of nerve, retinopathy, dysfunction of kidney); 9. Patients with serum creatinine = 1.5 mg/dL (133 umol/L); 10. Patients with a history of clinically significant heart disease (myocardial infarct, heart failure, and or severe cardiac rhythm); 11. Complicating severe infection, within 6 months after operation, severe trauma; 12. Patients with excess alcohol consumption=140g/week(male); = 70g/week(female); 13. Patients have participated other clinical trials within 24 weeks; 14. Patients with a history of drug allergy to TZDs and berberine; 15. Patients wth gestation or possible gestation or lactation, or males or females who expecting gestation during clinical trial; 16. Mental diseases patients; 17. Those who refuse to sign informed consent; 18. Any other conditions, which, in the opinion of the investigators would impede competence or compliance or possibility of hindering completion of the study; 19. Patients with serum triglyceride = 5.0 mmol/L; 20. Patients with thyroid disease, including hyperthyroidism or hypothyroidism. |
Country | Name | City | State |
---|---|---|---|
China | Department of Endocrinology and Metabolism,Shanghai Clinical Center of Diabetes,Shanghai Institute of Diabetes,The sixth people's Hospital Affiliated to Shanghai Jiaotong University | Shanghai | Shanghai |
China | Department of Endocrinology and Metabolism,The Fifth People's Hospital,Fudan University | Shanghai | Shanghai |
China | Endocrinology and Metabolism Department, Zhongshan Hospital, Fudan University, | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Xin Gao | Shanghai Jiao Tong University School of Medicine, Shanghai Municipal Science and Technology Commission |
China,
Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005 Jul;42(1):44-52. — View Citation
Fan JG, Zhu J, Li XJ, Chen L, Li L, Dai F, Li F, Chen SY. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol. 2005 Sep;43(3):508-14. — View Citation
Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004 Dec;10(12):1344-51. Epub 2004 Nov 7. — View Citation
Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2004 Sep;89(9):4312-9. — View Citation
Shadid S, Stehouwer CD, Jensen MD. Diet/Exercise versus pioglitazone: effects of insulin sensitization with decreasing or increasing fat mass on adipokines and inflammatory markers. J Clin Endocrinol Metab. 2006 Sep;91(9):3418-25. Epub 2006 Jun 27. — View Citation
Szapary PO, Bloedon LT, Samaha FF, Duffy D, Wolfe ML, Soffer D, Reilly MP, Chittams J, Rader DJ. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):182-8. Epub 2005 Nov 10. — View Citation
Yoneda M, Endo H, Nozaki Y, Tomimoto A, Fujisawa T, Fujita K, Yoneda K, Takahashi H, Saito S, Iwasaki T, Yamamoto S, Tsutsumi S, Aburatani H, Wada K, Hotta K, Nakajima A. Life style-related diseases of the digestive system: gene expression in nonalcoholic steatohepatitis patients and treatment strategies. J Pharmacol Sci. 2007 Oct;105(2):151-6. Epub 2007 Oct 6. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Improved metabolic parameters(glucose, lipid, liver enzymes, etc.) | improvement of the metabolic parameters, including serum glucose of OGTT, fasting glucose,2 hour glucose,area under the glucose curve and HbA1c,lipid profile(TC?TG?HDL-c?LDL-c?ApoA?ApoB?ApoE and Lpa),liver enzymes(ALT,AST,ALP,?-GT). | 16 weeks | |
Secondary | liver fat content | improvement of liver fat content by 1H NMR spectroscopy | 16 weeks | |
Secondary | serum insulin | improvement of serum insulin including fasting insulin,2 hour insulin and area under insulin curve. | 16 weeks | |
Secondary | the ratio of withdrawing because of inefficiency | 16 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06138327 -
A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria
|
Phase 1 | |
Completed |
NCT01045499 -
LAGB as a Treatment for Morbid Obesity in Adolescents
|
N/A | |
Completed |
NCT03674476 -
An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function
|
Phase 1 | |
Not yet recruiting |
NCT05495139 -
Gastric Bypass Stent Small-Sample-Size Study For Nonalcoholic Fatty Liver Disease
|
N/A | |
Completed |
NCT04988204 -
Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease
|
N/A | |
Recruiting |
NCT04369521 -
Evaluation of the Effects of a Low Free Sugar Diet in Patients With Nonalcoholic Fatty Liver Disease
|
N/A | |
Completed |
NCT01934777 -
Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis
|
Phase 3 | |
Enrolling by invitation |
NCT00983463 -
Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)
|
||
Recruiting |
NCT00658164 -
Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores
|
Phase 3 | |
Recruiting |
NCT02148471 -
Fatty Acids, Genes and Microbiota in Fatty Liver
|
N/A | |
Completed |
NCT06441409 -
Serum Ferritin Levels and Metabolic Dysfunction Associated Steatotic Liver Disease
|
N/A | |
Completed |
NCT03656744 -
A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
|
Phase 2 | |
Not yet recruiting |
NCT01735799 -
THE ASSOCIATION BETWEEN FATTY LIVER (NAFLD) DISEASE AND PCOS
|
N/A | |
Completed |
NCT01446276 -
Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver Disease
|
N/A | |
Completed |
NCT00930384 -
A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis
|
N/A | |
Recruiting |
NCT02469272 -
Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study
|
Phase 1 | |
Completed |
NCT02132780 -
Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease
|
N/A | |
Terminated |
NCT01355575 -
Rifaximin in Fatty Liver Disease
|
Phase 4 | |
Completed |
NCT01399645 -
Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes
|
Phase 2 | |
Completed |
NCT01210989 -
Trial of Hepaguard® in Adults With Nonalcoholic Steatohepatitis
|
N/A |